AzTrials
AzTrials

Extrahepatic Bile Duct CancerPhase 1NCT00486356

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

A Phase 1 study testing capecitabine, carboplatin and epirubicin hydrochloride in people with Extrahepatic Bile Duct Cancer and Gallbladder Cancer, run by University of Nebraska at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Read more about this study

Who is it for?
Ages 18 to 120 years
What is being tested?
capecitabine, carboplatin and epirubicin hydrochloride
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteUnited States
Study dates
1 Oct 2004to 1 Jan 2010
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Pathologically confirmed cancer, meeting 1 of the following criteria:
  • Disease that has progressed on standard therapy
  • Locally advanced but unresectable primary or recurrent solid tumor
  • Metastatic disease, including previously untreated metastatic disease for which study regimen represents reasonable initial chemotherapy with palliative intent (e.g., metastatic gastric cancer, hepatobiliary cancer, or cancer for which no effective standard therapy exists)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Absolute neutrophil count ≥ 2,000/mm³
Show all 17Show fewer
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) ≤ 2.5 times ULN
  • Creatinine ≤ 1.6 mg/dL
  • Left ventricular ejection fraction ≥ 50%
  • Fertile patients must use effective contraception
  • Recovered from prior therapy
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) or immunotherapy
  • At least 2 weeks since prior radiotherapy
  • At least 8 weeks since prior strontium therapy
  • At least 4 weeks since prior and no concurrent sorivudine or brivudine

Who cannot join

  • No other potentially curative treatment options available (e.g., surgery, radiotherapy, chemoradiotherapy, or combination chemotherapy)
  • No leukemia or lymphoma
  • No primary central nervous system (CNS) malignancies or CNS metastases
  • No other medical illness that would preclude study treatment
  • No active infection requiring IV antibiotic therapy unless the infection has resolved
  • No history of allergy to platinum compounds, mannitol, or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Show all 11Show fewer
  • No history of unexpectedly severe intolerance to fluorouracil
  • Not pregnant or nursing/negative pregnancy test
  • No prior doxorubicin at cumulative doses > 300 mg/m²
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent cimetidine

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Nebraska Medical Center, Eppley Cancer Center

    Omaha, Nebraska, 68198-6805

Other trials in United States

About this study

Official title: A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients

RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.

Read the detailed description

OBJECTIVES:

Primary

  • Determine the recommended phase II dose of capecitabine when given together with epirubicin hydrochloride and carboplatin in patients with progressive, unresectable, or metastatic cancer.
  • Determine the toxicities of this regimen in these patients.

Secondary

  • Correlate end-of-infusion levels of epirubicin hydrochloride and its metabolites with epirubicin hydrochloride dose and clinical toxicity in these patients.
  • Correlate the pharmacokinetics of capecitabine with clinical toxicity in these patients.
  • Determine the possible correlation between polymorphisms in the promoter region of the thymidylate synthase gene with clinical toxicity in these patients.
  • Document antitumor activity of this regimen in these patients.

OUTLINE: This is a dose-escalation study of capecitabine.

Patients receive epirubicin hydrochloride IV over 2 hours and carboplatin IV over 30 minutes on day 1 and oral capecitabine twice daily on days 2-5, 8-12, and 15-19. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Peripheral blood is collected for pharmacokinetic and pharmacogenetic studies before beginning study treatment and periodically during study. Samples for the pharmacogenetic studies are analyzed for correlation between polymorphisms in the promoter region of the thymidylate synthase gene and clinical toxicity. Patients also undergo bone marrow aspirate before beginning study treatment for molecular profiling studies.

Being tested
capecitabine, carboplatin, epirubicin hydrochloride, microarray analysis, polymorphism analysis
Keywords
unspecified adult solid tumor, protocol specific, recurrent gastric cancer, stage IV gastric cancer, advanced adult primary liver cancer, localized unresectable adult primary liver cancer, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, unresectable extrahepatic bile duct cancer, recurrent gallbladder cancer, unresectable gallbladder cancer
Medical subject headings
Bile Duct Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00486356
Study groupRoleWhat they receive
Capecitabine, Epirubicin, and CarboplatinExperimentalDetermine the recommended phase II dose of capecitabine when given together with epirubicin and carboplatin in treating patients with progressive, unresectable, or metastatic cancer.
Receives: Drug: capecitabine; Drug: carboplatin; Drug: epirubicin hydrochloride; Genetic: microarray analysis; Genetic: polymorphism analysis; Other: pharmacological study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recommended phase II dose of capecitabine

    Establish a recommended Phase II dose of oral capecitabine given twice daily on days 2-5, 8-12, and 15-19 in combination with fixed IV doses of epirubicin and carboplatin given day 1 of each 28-day cycle

    Measured: Every 28-days until first documented progression up to 63 months

  2. Toxicities of combined chemotherapy regimen

    Evaluate all toxicities associated with this combination chemotherapy regimen: 1 - mild, 2 - moderate, 3 = severe and 4 - life-threatening

    Measured: Every 28-days until first documented progression up to 63 months

Secondary outcomes (4)

  1. End-of-infusion levels of epirubicin hydrochloride/metabolites and incidence of correlation with epirubicin hydrochloride dosing and clinical toxicity

    Correlation of end-of-infusion levels of epirubicin hydrochloride and its metabolites with epirubicin hydrochloride dosing and clinical toxicity (1 - mild, 2 - moderate, 3 = severe and 4 - life-threatening)

    Measured: Each day of dosing up to 63 months

  2. Correlation of the pharmacokinetics (speed of appearance in the blood plasma and its concentration) of capecitabine with clinical toxicity

    Measure the pharmacokinetics of capecitabine and correlate these parameters with clinical toxicity

    Measured: Each day of dosing up to 63 months

  3. Incidence of Correlation between polymorphisms in the promoter region of the thymidylate synthase gene with clinical toxicity

    Assess possible correlation between polymorphisms in the promoter region of the thymidylate synthase gene with clinical toxicity

    Measured: Post-treatment up to 63 months

  4. Antitumor activity

    Document any anti-tumor activity (MTT assay is a quantitative and sensitive detection of cell proliferation as it measures the growth rate of cells by virtue of a linear relationship between cell activity and absorbance.)

    Measured: Prior to cycle 1, and then every two 28 day cycles up to 63 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2007 (estimated)
  2. Study start1 Oct 2004
  3. Primary completion1 Jan 2010
  4. Study completion1 Jan 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
46 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00486356
Sponsor's protocol ID
0284-04-FB
Other IDs
P30CA036727
Status last verified
Dec 2023
First submitted
13 Jun 2007
Last updated
3 Jan 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing capecitabine, carboplatin and epirubicin hydrochloride in people with Extrahepatic Bile Duct Cancer and Gallbladder Cancer, run by University of Nebraska at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recommended phase II dose of capecitabine (time frame: Every 28-days until first documented progression up to 63 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00486356.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in